Results 231 to 240 of about 214,376 (295)

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Clinical trial landscape and translational prospects of natural killer cell-based immunotherapy: an analysis based on the INFORMA database. [PDF]

J Immunother Cancer
Sun H, Zhang Y, Yuan Y, Liu D, Qiao J.
europepmc   +1 more source

Local delivery of interferon restores antigen presentation and sensitizes medulloblastoma to T cell killing. [PDF]

Proc Natl Acad Sci U S A
Eisemann T, Chambers KR, Beigi Masihi M, Tzaridis T, Gc S, Pister V, Youm I, Dutta A, Wenzel AT, Chin K, Xu Z, Pei Y, Pomeroy SL, Mesirov JP, Fraenkel E, Bagchi A, Chavez L, Wechsler-Reya RJ.   +17 more
europepmc   +1 more source

Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer. [PDF]

Front Immunol
Poggi A, Bruno V, Di Spirito A, Mortara L, Baci D.   +4 more
europepmc   +1 more source

Beyond KIR and NKG2A blockade: reprogramming NK-cell immunity in solid tumors. [PDF]

Front Cell Dev Biol
Pastorino C, Falco M, Giordano C, Zarefeizabadi N, Rutigliani M, Carbone A, Clavarezza M, Ortolani F, Nanni L, Della Chiesa M, Sivori S, Carlomagno S.   +11 more
europepmc   +1 more source

Advancing adoptive cellular immunotherapy via Notch-based ex vivo T cell development platforms. [PDF]

Biomed Pharmacother
Tuckett AZ, Zakrzewski JL.
europepmc   +1 more source

Emerging CAR-Treg and regulatory T cell therapies for inflammatory bowel diseases: a systematic review of a new era of treatment. [PDF]

Front Immunol
Suarez-Trujillo F, Steiner TS, Gisbert JP, Chaparro M.   +3 more
europepmc   +1 more source

Adoptive immunotherapy against sarcomas

Expert Opinion on Biological Therapy, 2014
Conventional treatments reached an unsatisfactory therapeutic plateau in the treatment of advanced unresectable bone and soft tissue sarcomas that remain an unsolved medical need. Several evidences support the concept that adoptive immunotherapy may effectively integrate within the complex and multidisciplinary treatment of sarcomas.In this work we ...
Mesiano, Giulia, Leuci, Valeria, Giraudo, Lidia, Gammaitoni, Loretta, Carnevale Schianca, Fabrizio, Cangemi, Michela, Rotolo, Ramona, Capellero, Sonia, Pignochino, Ymera, Grignani, Giovanni, Aglietta, Massimo, Sangiolo, Dario   +11 more
openaire   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Adoptive immunotherapy

Current Opinion in Oncology, 1997
Some of the most dramatic advances in the treatment of cancer have used the immune system in combination with conventional or transplantation chemotherapy. Adoptive immunotherapy has been used for relapses after allogeneic bone marrow transplantation, and it has been particularly effective for chronic myeloid leukemia.
K, Ballen, F M, Stewart
openaire   +2 more sources

Adoptive immunotherapy for cancer

Immunological Reviews, 2013
SummaryRecent clinical success has underscored the potential for immunotherapy based on the adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and durable clinical responses. This success has led to the broader evaluation of engineered T‐lymphocyte‐based adoptive cell therapy to treat a broad range of malignancies. In
Marco, Ruella, Michael, Kalos
openaire   +2 more sources